Praetego is committed to offering clinically meaningful drug candidates to patients at risk for AGE driven diseases. Starting with the microvascular and neurodegenerative complications of diabetes, Praetego’s platform is designed to limit disease progression. Praetego’s candidates (the Amadorins) are proprietary small molecules that inhibit the first step in the AGE pathway, a critical stage in halting the downstream damage.



AGE Pathway

Many of the diseases of aging are driven by a cascade of biochemical reactions called the AGE Pathway. AGEs are instigators of pathology. Once formed, they are irreversible. As AGEs accumulate in tissue, they signal an inflammatory response and impact tissue integrity. AGE accumulation promotes Oxidative Stress and Oxidative Stress promotes more AGE formation. This cycle is a powerful instigator of damage to the vascular system, nervous system, and many other organs in the body.   The results can be catastrophic. [See video Role of AGEs]


Amadorins Inhibit the AGE Pathway

Praetego’s technology inhibits AGE formation at the initial step. They function as chemical protectants and inhibit the reaction that drives AGE formation. By intervening at the initial step, an Amadorin drug candidate could limit the downstream consequences, including many of the chronic diseases of aging.


Serious Diabetic Complications

Serious Diabetic Complications stem from chronic insults to the vascular system from high blood glucose. This leads to damage of organs and tissues nourished by the microvascular system, including the nerves, kidneys, and eyes. Diabetic Peripheral Neuropathy, Nephropathy (Kidney Disease), and Retinopathy negatively impact quality of life. Without a way to slow or prevent damage to blood vessels, these conditions can become life threatening. Serious Diabetic Complications significantly increase the cost of care and decrease quality of life.

While there are many drugs to manage glucose control, there are almost none able to impact disease progression.